These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38294337)

  • 21. A randomized controlled trial to compare the effects of sulphonylurea gliclazide MR (modified release) and the DPP-4 inhibitor vildagliptin on glycemic variability and control measured by continuous glucose monitoring (CGM) in Brazilian women with type 2 diabetes.
    Vianna AGD; Lacerda CS; Pechmann LM; Polesel MG; Marino EC; Faria-Neto JR
    Diabetes Res Clin Pract; 2018 May; 139():357-365. PubMed ID: 29596951
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative effectiveness of gliclazide modified release versus sitagliptin as second-line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes.
    Zaccardi F; Jacquot E; Cortese V; Tyrer F; Seidu S; Davies MJ; Khunti K
    Diabetes Obes Metab; 2020 Dec; 22(12):2417-2426. PubMed ID: 32761768
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of vildagliptin relative to sulfonylurea as dual therapy with metformin (or as monotherapy) in Muslim patients with type 2 diabetes fasting during Ramadan in the Middle East: the VIRTUE study.
    Hassoun AA; Al-Arouj M; Ibrahim M
    Curr Med Res Opin; 2017 Jan; 33(1):161-167. PubMed ID: 27684469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of replacing sitagliptin with canagliflozin in real-world patients with type 2 diabetes uncontrolled with sitagliptin combined with metformin and/or gliclazide: The SITA-CANA Switch Study.
    Garcia de Lucas MD; Pérez Belmonte LM; Suárez Tembra M; Olalla Sierra J; Gómez Huelgas R
    Diabetes Metab; 2018 Sep; 44(4):373-375. PubMed ID: 29859992
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and Safety of Use of the Fasting Algorithm for Singaporeans With Type 2 Diabetes (FAST) During Ramadan: A Prospective, Multicenter, Randomized Controlled Trial.
    Lum ZK; Khoo ZR; Toh WYS; Kamaldeen SAK; Shakoor A; Tsou KYK; Chew DEK; Dalan R; Kwek SC; Othman N; Lian JX; Bte Sunari RN; Lee JY
    Ann Fam Med; 2020 Mar; 18(2):139-147. PubMed ID: 32152018
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diabetes and Ramadan: an update on use of glycemic therapies during fasting.
    Ahmed MH; Abdu TA
    Ann Saudi Med; 2011; 31(4):402-6. PubMed ID: 21727749
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic study.
    Aravind SR; Ismail SB; Balamurugan R; Gupta JB; Wadhwa T; Loh SM; Suryawanshi S; Davies MJ; Girman CJ; Katzeff HL; Radican L; Engel SS; Wolthers T
    Curr Med Res Opin; 2012 Aug; 28(8):1289-96. PubMed ID: 22738801
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of Type 2 Diabetes with a Breakable Extended Release Gliclazide Formulation in Primary Care: The Xrise Study.
    Mohan V; Chopra V; Sanyal D; Jain S; Jayaprakashsai J
    J Assoc Physicians India; 2015 Dec; 63(12):26-29. PubMed ID: 27666900
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation between pre-ramadan glycemic control and subsequent glucose fluctuation during fasting in adolescents with Type 1 diabetes.
    Afandi B; Kaplan W; Al Hassani N; Hadi S; Mohamed A
    J Endocrinol Invest; 2017 Jul; 40(7):741-744. PubMed ID: 28239763
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The characteristics and pattern of care for the type 2 diabetes mellitus population in the MENA region during Ramadan: An international prospective study (DAR-MENA T2DM).
    Hassanein M; Al Awadi FF; El Hadidy KES; Ali SS; Echtay A; Djaballah K; Dessapt-Baradez C; Khazaal FAK; Abu-Hijleh MO; Al Shaikh A; Gharbi MEH; Shehadeh N; Bennakhi A; Al Arouj M
    Diabetes Res Clin Pract; 2019 May; 151():275-284. PubMed ID: 30825560
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diamicron MR once daily is effective and well tolerated in type 2 diabetes: a double-blind, randomized, multinational study.
    Drouin P
    J Diabetes Complications; 2000; 14(4):185-91. PubMed ID: 11004426
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents.
    Chan SP; Colagiuri S
    Diabetes Res Clin Pract; 2015 Oct; 110(1):75-81. PubMed ID: 26361859
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fasting during the holy month of Ramadan among older children and adolescents with type 1 diabetes in Kuwait.
    Mohamed K; Al-Abdulrazzaq D; Fayed A; El Busairi E; Al Shawaf F; Abdul-Rasoul M; Shaltout AA
    J Pediatr Endocrinol Metab; 2019 Aug; 32(8):843-849. PubMed ID: 31318694
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk stratification using the 2021 IDF-DAR risk calculator and fasting experience of Bangladeshi subjects with type 2 diabetes in Ramadan: The DAR-BAN study.
    Kamrul-Hasan ABM; Alam MS; Kabir MA; Chowdhury SR; Hannan MA; Chowdhury EUR; Ahsan MM; Mohana CA; Iftekhar MH; Hasan MJ; Talukder SK
    J Clin Transl Endocrinol; 2023 Mar; 31():100315. PubMed ID: 36861141
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Validity of the International Diabetes Federation risk stratification score of Ramadan fasting in individuals with diabetes mellitus.
    Alfadhli EM; Alharbi TS; Alrotoie AM; Aljohani AA; Qari AS; Alsubhi BA; Alsaedi AH; Aljohani AA
    Saudi Med J; 2024 Jan; 45(1):86-92. PubMed ID: 38220239
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of fasting during Ramadan on the glycemic control of patients with type 2 diabetes mellitus.
    Sahin SB; Ayaz T; Ozyurt N; Ilkkilic K; Kirvar A; Sezgin H
    Exp Clin Endocrinol Diabetes; 2013 Oct; 121(9):531-4. PubMed ID: 23934679
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Verification of 2021 IDF-DAR risk assessment tool for fasting Ramadan in patients with diabetes attending primary health care in The Kingdom of Bahrain: The DAR-BAH study.
    Shamsi N; Naser J; Humaidan H; Al-Saweer A; Jaafar M; Abbas F; Al-Doseri S; Shabeeb N; Al-Shaikh E; Al-Dairi A; Mandoos K
    Diabetes Res Clin Pract; 2024 May; 211():111661. PubMed ID: 38604445
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and Effectiveness of Insulin Glargine 300 U/mL in Participants with Type 2 Diabetes Who Fast During Ramadan in The Gulf Region: A Subgroup Analysis of the Real-World ORION Study.
    Malik RA; Elhadd T; Alattar A; Al Shaikh A; Al Randi M; Arora R; Al-Sifri S; Akil Y; Magdy A; Naqvi M; Hassanein M
    Diabetes Ther; 2022 Mar; 13(3):569-581. PubMed ID: 35239165
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Real-World Observational Study of Gla-300 in Adults with Type 2 Diabetes Who Fast During Ramadan in the South Asia Region: A Subgroup Analysis of the ORION Study.
    Hassanein M; Sahay R; Hasan MI; Hussain A; Mittal V; Mohammed R; Shaikh Z; Farishta F; Mohanasundaram S; Naqvi M; Nair A; Ali Z
    Diabetes Ther; 2022 Apr; 13(4):747-759. PubMed ID: 35286607
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results.
    Ristic S; Collober-Maugeais C; Cressier F; Tang P; Pecher E
    Diabetes Obes Metab; 2007 Jul; 9(4):506-11. PubMed ID: 17587393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.